Article Versions Notes

Eissa IH, Alesawy MS, Saleh AM, Elkaeed EB, Alsfouk BA, El-Attar A-AMM, Metwaly AM. Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs. Molecules. 2022; 27(7):2287. https://doi.org/10.3390/molecules27072287

Eissa, Ibrahim H., Mohamed S. Alesawy, Abdulrahman M. Saleh, Eslam B. Elkaeed, Bshra A. Alsfouk, Abdul-Aziz M. M. El-Attar, and Ahmed M. Metwaly. 2022. "Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs" Molecules 27, no. 7: 2287. https://doi.org/10.3390/molecules27072287

Eissa, I. H., Alesawy, M. S., Saleh, A. M., Elkaeed, E. B., Alsfouk, B. A., El-Attar, A. -A. M. M., & Metwaly, A. M. (2022). Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs. Molecules, 27(7), 2287. https://doi.org/10.3390/molecules27072287